



HHS Public Access

Author manuscript

J Abnorm Psychol. Author manuscript; available in PMC 2022 November 01.

Published in final edited form as:

J Abnorm Psychol. 2021 November ; 130(8): 829–840. doi:10.1037/abn0000716.

Increased Inflammation Predicts 9-Year Change in Major Depressive Disorder Diagnostic Status

Nur Hani Zainal, M.S., Michelle G. Newman, Ph.D.

Department of Psychology, The Pennsylvania State University, University Park

Abstract

Background: *Cytokine theory of depression* proposes that increased baseline inflammatory activity, may accumulate over time and lead to future major depressive disorder (MDD). However, most research conducted on this topic has been cross-sectional and examined between- (vs. within-) persons and symptom severity (vs. diagnosis). Therefore, we tested if elevated inflammatory activity at Time 1 (T1) would predict future *within*-person 9-year change in MDD diagnosis.

Method: Community-dwelling adults ($n = 945$) participated in the Midlife Development in the United States (MIDUS) study. T1 and T2 MDD status was assessed using the Composite International Diagnostic Interview–Short Form, and markers of inflammatory activity at T1 were measured (e.g., levels of serum interleukin-6 (IL-6), C-reactive protein (CRP), fibrinogen). Latent change score modeling was conducted.

Results: Higher T1 IL-6, CRP, and fibrinogen levels of inflammatory activity predicted T1-T2 development/relapse of MDD within persons. This effect occurred more strongly among women (vs. men) ($d = 0.149$ vs. 0.042), younger (vs. older) adults ($d = 0.137$ vs. 0.119), persons with more (vs. less) chronic health issues ($d = 0.133$ vs. 0.065), low (vs. middle- or high-) income earners ($d = 0.161$ vs. 0.050), and persons with more (vs. less) frequency childhood trauma ($d = 0.156$ vs. 0.017).

Conclusions: Findings aligned with expanded cytokine theories which posit that the impact of increased T1 inflammatory activity on future change in MDD status would be larger for subgroups vulnerable to increased stress exposure. Cognitive-behavioral or pharmacological approaches to reduce markers of inflammatory activity may prevent development/relapse of MDD.

General Scientific Summary

Increased C-reactive protein (CRP), fibrinogen, and interleukin-6 (IL-6) levels predicted 9-year major depressive disorder (MDD) diagnostic status change more strongly in younger than older adults, women but not men, those with low (vs. high) income, as well as persons with high (vs. low) childhood trauma frequency and number of chronic illnesses. Findings aligned with expanded cytokine theories (e.g., social signal transduction theory of depression) which posit that markers of inflammatory activity predict future change in MDD status especially for populations vulnerable

Correspondence concerning this article should be addressed to Nur Hani Zainal, Department of Psychology, The Pennsylvania State University, University Park, PA 16802. nvz5057@psu.edu. Telephone: 814-863-0115.

Conflict of interest

The authors do not have any conflicts of interest or financial disclosures.

to heightened, chronic, and longterm exposure to environmental stressors. Continued efforts to empirically test expanded cytokine theories of depression may improve delineation of patterns of health disparities and facilitate effective measures to prevent the onset or recurrence of MDD.

Keywords

major depressive disorder; inflammation; latent change; etiology

Major depressive disorder (MDD) is a common psychiatric disorder observed in the general population characterized by symptoms such as depressed mood, sleep disturbance, fatigue, difficulty concentrating, low self-worth, and suicidality (Kessler & Wang, 2008). MDD can incur large costs to individuals and societies, as it has been linked consistently to reduced quality of life, relationship satisfaction, job performance, and personal monthly income (Beutel, Glaesmer, Wiltink, Marian, & Brähler, 2010; Dismuke & Egede, 2010; Jacobson & Newman, 2016; Kessler et al., 2008), as well as persistent health problems. Myriad health issues include autoimmune, cardiovascular, endocrine, and neurocognitive disease (Bialek, Czarny, Strycharz, & Sliwinski, 2019; Butnorienė et al., 2015; Zainal & Newman, 2021, in press-a). Consequently, MDD creates a large economic burden to healthcare systems and governments globally (e.g., accounting for 62% of total annual healthcare costs in Europe) (DiLuca & Olesen, 2014). Therefore, understanding risk factors for MDD is important.

One such risk factor may be increased inflammatory activity. The *cytokine theory of depression* (Miller, Haroon, Raison, & Felger, 2013; Miller, Maletic, & Raison, 2009) posits that excessive peripheral bloodstream levels of markers of inflammatory activity may be actively transported to the brain and persistently interact with neurotransmitter metabolism, hormonal function, and neuroplasticity. Increased cytokines have been shown to trigger the secretion and buildup of corticotropin-releasing hormones, adrenocorticotropic hormones, and cortisol in the HPA axis. This is a feature reliably observed in persons with elevated MDD symptoms across multiple time-points (e.g., Milrad et al., 2018; Pariante & Miller, 2001). Also, the theory posits that chronic or excessive activation of cytokine networks in the central nervous system may lead to altered glutamatergic, serotonergic, or dopaminergic activation, apoptosis, and oxidative stress in pertinent cell forms (e.g., oligodendrocytes, astrocytes) over time (Haroon & Miller, 2017; Miller & Raison, 2016; Shelton et al., 2011; Treadway, Cooper, & Miller, 2019). Peripheral cytokines might also compromise immunity, growth, and development of nerve tissue (Kim, Na, Myint, & Leonard, 2016; Rajkowska & Miguel-Hidalgo, 2007). Additionally, it is thought that increased inflammatory activity can predict future MDD via abnormalities of reciprocal actions between glia or neurotransmitters and brain regions that regulate mood or cognitive functioning (e.g., hippocampus, prefrontal cortex, ventral striatum, dorsolateral anterior cingulate cortex; Páv, Kovár, Fiserová, Havrdová, & Lisá, 2008; Tilleux & Hermans, 2007). Collectively, cytokine theory posits that increased inflammatory activity can predict future MDD.

Myriad markers of inflammatory activity form part of our highly complex immune system. These include interferons (IFN), interleukin-6 (IL-6), IL-8, IL-1 β , C-reactive protein (CRP),

and tumor necrosis factor (Beurel, Toups, & Nemeroff, 2020). There are also many possible biomarkers implicated in the etiology/relapse of MDD. Included among them are excessive levels of baseline IL-6, CRP, and/or fibrinogen (Chu et al., 2019; de la Torre-Luque, Ayuso-Mateos, Sanchez-Carro, de la Fuente, & Lopez-Garcia, 2019; Eswarappa, Neylan, Whooley, Metzler, & Cohen, 2019; Fancourt & Steptoe, 2020; Gimeno et al., 2009; Hamer, Molloy, de Oliveira, & Demakakos, 2009; Kang et al., 2016; Khandaker, Pearson, Zammit, Lewis, & Jones, 2014; Lamers et al., 2019; Smith, Au, Ollis, & Schmitz, 2018; Valkanova, Ebmeier, & Allan, 2013; Wium-Andersen, Ørsted, Nielsen, & Nordestgaard, 2013; Zalli, Jovanova, Hoogendijk, Tiemeier, & Carvalho, 2016). Thus, our study examined these three biomarkers.

The proinflammatory cytokine IL-6 strongly catalyzes the creation and secretion of related markers of inflammatory activity such as acute phase protein, C-reactive protein (CRP), and coagulation protein fibrinogen (Heinrich, Castell, & Andus, 1990). Fibrinogen and CRP are acute phase proteins (Ridker, 2016) that the liver releases upon increase in IL-6 levels. IL-6 is secreted by activated T cells and macrophages as well as nonimmune cells (e.g., adipose, osteoblastic cells, smooth muscle) and monocytes (Rose-John, 2018). Excessive levels of IL-6 have been implicated in the etiology of MDD through chronic alterations to the hypothalamic-pituitary-adrenal (HPA) or neurotransmitter metabolism (Ting, Yang, & Tsai, 2020). CRP mainly functions to unite with phospholipid species of pathogens or injured cells to trigger the complement system. As tissue impairments could have diverse causes, increased high-sensitivity CRP indicates a general inflammatory response as opposed to being ascribed to a specific cause (Macleod & Avery, 1941). Excessive CRP may predict future MDD by activation of the enzyme, indoleamine-2,3-dioxygenase (IDO), which could thereby raise production of quinolinic and kynurenic acids and reduce creation of serotonin (Capuron & Miller, 2011). In addition, fibrinogen performs a coagulation function as an antecedent of fibrin and contributes to platelet aggregation in response to tissue and vascular injury (Koenig, 2003). During chronic inflammation, the liver synthesizes excessive quantities of fibrinogen (Herrick, Blanc-Brude, Gray, & Laurent, 1999). Fibrinogen thus might play a role in the development of MDD by adversely affecting cardiovascular systems (Duijvis et al., 2011).

Abundant data buttress both the short-term and longterm effects posited by the cytokine theory of depression. Meta-analytic evidence combined across more than 30 cross-sectional studies found that greater depression severity was consistently and independently associated with increased bloodstream levels of IL-6, CRP, fibrinogen, or related biomarkers (e.g., TNF) (Dowlati et al., 2010; Haapakoski, Mathieu, Ebmeier, Alenius, & Kivimäki, 2015; Hiles, Baker, de Malmanche, & Attia, 2012). However, such cross-sectional data does not establish the temporal precedence of increased markers of inflammatory activity as a risk factor (Höfler, 2005). Prospective studies are thus required to clarify if and how inflammatory activity precedes and predicts future MDD symptoms or diagnosis.

Thus far, 18 empirical studies have tested if baseline levels of IL-6, CRP, or fibrinogen were linked to future heightened depression or related constructs across many years. Excessive IL-6, CRP, or fibrinogen at baseline predicted elevated depression severity, persistence, or reduced well-being and physical activity 4 to 12 years later in community-dwelling British children, adolescents, young-to-middle aged adults (Chu et al., 2019; de la Torre-Luque

et al., 2019; Fancourt & Steptoe, 2020; Hamer et al., 2009; Khandaker et al., 2014; Zalli et al., 2016) and civil servants (Gimeno et al., 2009). Likewise, greater initial levels of IL-6 were related to MDD diagnostic status and chronicity across 1 to 10 years among non-statin-medicated stroke patients in South Korea (Kang et al., 2016) and community-dwelling adults in the Netherlands (Lamers et al., 2019) and Spain (de la Torre-Luque et al., 2019). Correspondingly, higher CRP level predicted greater psychological distress, depression symptoms, or risk for hospitalization with depression 4 to 12 years later in young (18–40 years), middle-aged (41–64 years), or older adults (65 years and older) in Denmark (Wium-Andersen et al., 2013). Moreover, increased fibrinogen, CRP, and erythrocyte sedimentation rate were associated with higher 4-year depression and post-traumatic stress disorder symptoms in U.S. veterans (Eswarappa et al., 2019). In a similar vein, meta-analytic data pooled across 7 prospective studies in older adults showed that increased IL-6 and CRP predicted higher future depression severity over 2 to 6 years (Smith et al., 2018). Overall, the data suggest that higher levels of IL-6, CRP, and fibrinogen may precede and predict longterm change in future MDD diagnostic status.

Building on cytokine theory, the *social signal transduction theory of depression* (Slavich & Irwin, 2014) and its extension, the *social safety theory* (Slavich, 2020a), propose that the inflammation-future MDD connection is stronger among subgroups with heightened biopsychosocial vulnerabilities (Majd, Saunders, & Engeland, 2020). Supporting this idea, increased inflammatory activity has been linked to elevated depression among more women than men (Köhler-Forsberg et al., 2017), and such a pattern has been attributed to hormonal, cognitive style, social, and lifestyle variations (e.g., less physical activity) (Derry, Padin, Kuo, Hughes, & Kiecolt-Glaser, 2015; Slavich & Sacher, 2019). Further, it is possible that the inflammation-future MDD relation would be stronger for persons with more chronic health conditions (Patten et al., 2018). Moreover, it is plausible that inflammation would have a larger association with future MDD in persons with more (vs. less) frequent exposure to childhood abuse or neglect (Hostinar, Lachman, Mroczek, Seeman, & Miller, 2015; Nusslock & Miller, 2016). Relatedly, based on these theories (Morozink, Friedman, Coe, & Ryff, 2010; Slavich, 2020a), it stands to reason that increased inflammatory activity would forecast future MDD for lower- (vs. middle or higher-) income earners afflicted with more financial, social, and related life stressors.

Thus, building on the aforesaid data and based on the cytokine theory of depression, this study aimed to determine if an increased latent factor composed of IL-6, CRP, and fibrinogen levels would be associated with future within-person 9-year change in MDD status in community-dwelling adults. By using structural equation modeling (SEM) with *latent change score* (LCS) approaches, we were able to expand on prior longitudinal between-person studies in several ways. First, LCS methods adjust for between-person, cross-sectional effects. In addition, they control for regression to the mean and minimize measurement error (Zainal & Newman, 2019). Moreover, LCS permitted us to examine *within-person change* in MDD status across 9 years. Further, this study adds to literature by examining the moderators of the within-person relation between increased inflammation and future change in MDD status. Most prior research on this topic used ordinary least squares regression (Eswarappa et al., 2019; Gimeno et al., 2009; Hamer et al., 2009; Kang et al., 2016; Khandaker et al., 2014; Smith et al., 2018; Wium-Andersen et al., 2013; Zalli et al.,

2016). Doing so only informs *between*-person relations and does not account for clustering of repeated measures within persons across time (Grimm, Ram, & Hamagami, 2011; Huang, 2018). Specifically, we aimed to test expanded cytokine theories of depression (e.g., Majd et al., 2020; Slavich, 2020a) and predicted that T1 inflammatory activity would positively predict 9-year T1-T2 change in MDD status for the entire sample (non-moderated main effect hypothesis (Hypothesis 1; H1). We also hypothesized that the inflammation-future change in MDD status relation would be stronger among the following subgroups with more biopsychosocial vulnerabilities: older vs. younger adults (H2); women vs. men (H3); persons facing higher (vs. lower) number of chronic health conditions (H4); persons exposed to more (vs. less) frequent childhood maltreatment (H5); and lower (vs. middle- or higher-) income earners (H6).

Method

Participants

This was a secondary analysis of the publicly available Midlife Development in the United States (MIDUS) dataset (Ryff et al., 2019a; Ryff, Seeman, & Weinstein, 2019b; Ryff & Davidson, 2019). Participants ($n = 945$) were community-dwelling adults aged 54.33 years on average ($SD = 11.06$, range = 34–83). Females comprised 52.78% of the sample, 20.42% attained a college education, and 95.37% identified as White relative to African American, Asian, Pacific Islander, or other ethnicities.

Measures

The present study focused on participants who voluntarily consented to complete the in-person MDD diagnostic interview and biomarker data collection at Time 1 (T1) conducted in 2004, as well as another follow-up psychiatric diagnostic interview at T2 in 2013. Whereas the MDD diagnostic interview was carried out at T1 and T2, the biomarker data collection was performed only at T1.

T1 and T2 MDD Diagnostic Interview.—The Diagnostic and Statistical Manual of Mental Disorders—Third Edition—Revised (DSM-III-R)-consistent Composite International Diagnostic Interview—Short Form (CIDI-SF) (American Psychiatric Association, 1987; Kessler, Andrews, Mroczek, Ustun, & Wittchen, 1998; Wittchen, 1994) was used to assess MDD at T1 and T2. The CIDI-SF MDD module asked whether participants experienced depressed mood or anhedonia in the past 12 months, and associated symptoms of fatigue, appetite changes, sleep difficulties, trouble concentrating, worthlessness, and/or suicidal ideation. The instrument has strong sensitivity (.939) and specificity (.896) for MDD. It has also shown high internal consistency and good retest-reliability for its continuous scale, and high concordance with the DSM-Fourth Edition (DSM-IV) clinical interview as a diagnostic measure (Kessler et al., 1998; Kessler & Üstün, 2004; Wang, Berglund, & Kessler, 2000).

T1 Inflammatory Activity.—Following overnight fasting, respondents offered biomarkers based on an established protocol (Love, Seeman, Weinstein, & Ryff, 2010). The biomarker samples were frozen at -60° to -80°C using dry ice and shipped to the MIDUS Biocore Laboratory, where they were stored at -65°C for monthly batch evaluations to ensure

consistency across laboratories involved in the data collection (Ryff et al., 2019b). IL-6 was measured from participants' blood serum using the enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN) (Friedman & Herd, 2010). CRP was assessed using a particle-enhanced immunonephelometric instrument (Dade Behring Inc., Deerfield, IL) (Friedman & Herd, 2010). Likewise, the BNII nephelometer (N Antiserum to Human Fibrinogen) at the same laboratory (Dade Behring Inc., Deerfield, IL) was used to measure fibrinogen (Hostinar et al., 2017). In addition, a partially automated and adapted Claus method was used to examine blood serum on a BNII nephelometer (Clauss, 1957). The researchers computed all inflammation level values in duplicate; markers of inflammatory activity that were > 10 pg/mL were reanalyzed and rerun in diluted sera to conform to the normal distribution (Love et al., 2010). For all of these markers of inflammatory activity, the coefficients of variance within- and between-laboratories fell within normal limits (< 12%).

Potential Moderators.—Participants reported on the following variables: age (in years), gender (male vs. female), annual income (reported based on wages, pension, or supplemental security income), body mass index (BMI; kg/m²), frequency of exposure to childhood abuse or neglect, and number of chronic health conditions. The specific health problems assessed in the metric of total number of chronic health condition were as follows: past-year diseases or problems related to AIDS/HIV, alcohol/drug, asthma, backache, bladder, bones, constipation, diabetes, dry/sore skin, face rash, foot, gall bladder, gum/mouth, hair loss, hand rash, hay fever, hernia, hypertension, itch, lung, lupus, piles/hemorrhoids, migraine, neurological disorders, pimples, skin, sleep, stomach, stroke, swallowing, sweating, thyroid, tuberculosis, ulcer, varicose veins, warts). Also, frequency of childhood trauma was assessed using the 25-item Childhood Trauma Questionnaire (Bernstein & Fink, 1998) for which participants endorsed items on a 5-point Likert scale ranging from 1 = *never true* to 5 = *very often true* (possible total score range = 25–125).

Data Analyses

SEM analyses were conducted using the *lavaan R* package (Rosseel, 2012) with *RStudio* software (Version 1.3.959). We used practical fit indices, confirmatory fit index (CFI; Bentler, 1990) and root mean square error of approximation (RMSEA; Steiger, 1980), to assess model fit. Next, to examine T1-T2 change in MDD status (i.e., autoregressive self-feedback parameter), establish temporal precedence, and partition between- and within-person effects, we used LCS models (McArdle, 2011, 2009). As LCS models move closer toward causal inference by combining latent growth and cross-lagged panel SEM (Grimm & Ram, 2018), they could determine if increased T1 inflammatory activity predicted within-person 9-year T1-T2 change in MDD diagnosis status. Therefore, LCS measured true, within-person change of a variable of interest over 2 successive time-points while attenuating measurement error (Zainal & Newman, in press-b). The course of MDD status is a function of its initial status and latent change score between two successive time-points. Equation (1) examines within-person change in MDD status:

$$\Delta D_{[T1 - T2]} = \alpha_D * D_S + \beta_S * D_{[T1]} \quad (1)$$

where $D_{[T1-T2]}$ signifies the latent change in MDD status from T1 to T2, α_D indicates the between-person constant change parameter linked to the latent slope of MDD status, D_S , and β_S indicate the within-person self-feedback loop of MDD status (or T1 MDD status, $D_{[T1]}$, predicting its future change). Equation (1) denotes the dual LCS model, such that the between-person *constant change* parameter (α_D) and within-person proportional effect (β_S) models course of change in MDD status between two successive time-points. Equation (2) expands on equation (1) by adding a *within-person level-to-change coupling parameter* (δ_D):

$$\Delta D_{[T1 - T2]} = \alpha_D * D_S + \beta_S * D_{[T1]} + \delta_C * C_{[T1]} \quad (2)$$

The δ_C indicates the *within-person coupling effect* of latent inflammatory activity composite predicting T1-T2 change in MDD status. We obtained a latent T1 inflammatory activity index based on serum levels of IL-6, CRP, and fibrinogen using CFA, as this approach enhances power and reduces measurement error (Tomarken & Waller, 2005). Further, we presented unstandardized regression coefficients (β_s) and standard errors (*SEs*) herein.

Following recommendations (Graham, 2005; Jacobson & Newman, 2014; Maslowsky, Jager, & Hemken, 2015), we also conducted a series of moderator analyses (H2–H6). Specifically, we assessed the degree to which LCS parameter estimates were moderated by below median vs. at or above median values of continuous variables (age, annual income, number of chronic health conditions, childhood trauma frequency) (Iacobucci, Posavac, Kardes, Schneider, & Popovich, 2015) and a categorical variable (women vs. men) (i.e., we dichotomized continuous variables to allow for testing of group differences in model equivalence). Group differences were evaluated by constraining the factor loadings and regression coefficients to be equal across groups, and by inspecting any statistically significant change in the χ^2 fit index (χ^2) between the fully constrained model (restrict all factor loadings and regression coefficients to be equal) and the freely estimated model (restrict all factor loadings to be equal but freely estimate all regression coefficients) (Graham, 2005; Jacobson & Newman, 2014). Although covarying variables is common practice, we decided to examine moderator effects instead because covarying prevents detecting potential moderator influences (Majd et al., 2020).

In total, 1.91% of the data was missing. We managed the missing data using full information maximum likelihood as it uses all available information (vs. listwise deletion) and because the data was missing at random (Little's MCAR test: $\chi^2(24) = 28.73, p = .230$). Effect sizes were computed with the formula: Cohen's $d = t / (2(1 - r)/N)$, where $r = (t^2 / (t^2 + df))$. Note that t is the t -statistic of the parameter estimate, N is the sample size, and df is the degrees of the error term (Dunlap, Cortina, Vaslow, & Burke, 1996; Dunst, Hamby, & Trivette, 2004).

Results

Confirmatory Factor Analysis of Latent Inflammatory Activity Composite

Following an exploratory factor analysis of the six inflammatory markers in the current dataset, CFA supported the fit of a 1-factor model for three markers of inflammatory activity IL-6, CRP, and fibrinogen ($\chi^2(df = 1) = 0.090, p = .762, CFI = 1.000, RMSEA = .000$).

Moreover, the standardized factor loadings were statistically significant (all $p < .001$) and high for IL-6 (.612), CRP (.823), and fibrinogen (.579). Further, the mean (or intercepts) (IL-6: 0.679; CRP: 0.312; fibrinogen: 5.792) and residual variances (IL-6: 0.626; CRP: 0.323; fibrinogen: 0.665; latent inflammatory activity composite: 1.000) were all statistically significant (all $p < .001$).¹

Testing Non-Moderated Main Effect Hypothesis (H1)

Based on the pattern of fit indices, the model showed good fit ($\chi^2(df=6) = 15.78, p = .015, CFI = .974, RMSEA = .042, 95\% CI [.017, .068]$). Within persons, increased T1 latent inflammatory activity was significantly associated with future 9-year change in MDD status ($\beta = 0.065, SE = 0.027, p = .016, d = 0.159$). This effect of baseline inflammatory activity predicting future latent change in MDD status was significant even after adjusting for the self-feedback loop ($\beta = -0.711, SE = 0.054, p < .001, d = -0.872$) and other parameters in the LCS model. Collectively, the results were consistent with H1.

Testing Moderator Hypotheses (H2–H6)

Age emerged as a moderator, such that increased T1 inflammatory activity predicted change in T1-T2 MDD status significantly more strongly among younger (vs. older) adults ($\chi^2(4) = 8.795, p = .046$). Simple slopes analyses showed that increased T1 inflammatory activity significantly predicted 9-year change in MDD status among adults below the median age of 45 years ($\beta = 0.085, SE = 0.041, p = .039, d = 0.137$). However, no relation was found between T1 inflammatory activity and T1-T2 change in MDD status for persons at or above age 45 ($\beta = 0.063, SE = 0.035, p = .073, d = 0.119$). Therefore, H2 which posited stronger effects in *older* as opposed to younger adults, was not supported. Table 1 displays the regression weights and factor loadings.²

Gender also presented as a moderator. Increased T1 inflammatory activity predicted 9-year change in MDD status more strongly in females than males ($\chi^2(4) = 14.996, p < .001$). Simple slopes analyses revealed that T1 inflammatory activity predicted 9-year future change in MDD status in females ($\beta = 0.082, SE = 0.037, p = .024, d = 0.149$). However, no relation between T1 inflammatory activity and 9-year change in MDD status was found in males ($\beta = 0.023, SE = 0.037, p = .636, d = 0.042$). Thus, findings were consistent with H3 (see Table 2).

T1 inflammatory activity level predicted future change in MDD status considerably more strongly among persons with more (vs. fewer) chronic health conditions ($\chi^2(4) = 9.119, p = .050$). Simple slopes analyses showed that increased T1 inflammatory activity predicted

¹An expanded explanation on how the biomarkers (IL-6, CRP, and fibrinogen) were selected using a series of EFA (Lim & Jahng, 2019; Lubbe, 2019; Matsunaga, 2010; Revelle, 2020; Rosellini & Brown, 2021; Watkins, 2005) and CFA was included in the Supplementary Materials on pages 5 to 6.

²Based on a reviewer comment, we were curious whether this effect was driven by a healthy older population and therefore, grouped participants into 10-year age cohort categories (see Table S1 in the online supplementary materials) and examined mean chronic health conditions. This led us to conclude that this counter-intuitive age moderator effect was likely driven by a particularly healthy group of persons above 80 years of age ($n = 6$) whose mean number of chronic health conditions were substantially lower than most other age groups at T2. Upon removing these 6 participants, the age moderator findings were no longer significant. The revised moderator analysis indicated that age did not moderate the effect of inflammatory activity level on 9-year MDD status change ($\chi^2(4) = 6.200, p = .185$). Higher inflammatory activity level was significantly related to 9-year MDD status change in both younger adults ($\beta = 0.073, SE = 0.027, p = .008, d = 0.136$) and older adults ($\beta = 0.073, SE = 0.027, p = .008, d = 0.136$).

9-year future change in MDD status for persons with 3 or more chronic health conditions ($\beta = 0.074$, $SE = 0.036$, $p = .044$, $d = 0.133$). Conversely, for those with 2 or less chronic health conditions, increased T1 inflammatory activity did not predict latent 9-year change in MDD status ($\beta = 0.043$, $SE = 0.044$, $p = .324$, $d = 0.065$). Thus, the results were congruent with H4. Table 3 presents the regression weights and factor loadings for H4.

Also, analyses demonstrated income to be a moderator; increased T1 inflammatory activity predicted future 9-year change in MDD status substantially more strongly among lower (vs. higher) income earners ($\chi^2(4) = 34.659$, $p < .001$). Simple slopes analyses showed that elevated increased T1 inflammatory activity significantly predicted future 9-year change in MDD status in persons with an annual income below the median level of \$38,750 ($\beta = 0.096$, $SE = 0.039$, $p = .015$, $d = 0.161$). However, increased T1 inflammatory activity was not related to 9-year latent change in MDD status in those earning annual income at or above the median level ($\beta = 0.025$, $SE = 0.033$, $p = .452$, $d = 0.050$). Therefore, the findings aligned with H5 (see Table 4).

Further, increased T1 inflammatory activity predicted subsequent change in MDD status significantly more strongly among persons with at or above median (vs. lower) CTQ score of 33 ($\chi^2(4) = 39.180$, $p < .001$). Simple slopes analyses showed that increased T1 inflammatory activity significantly predicted future 9-year change in MDD status for persons with at or above the median childhood trauma frequency (CTQ score of 33) ($\beta = 0.095$, $SE = 0.042$, $p = .024$, $d = 0.156$). However, increased T1 inflammatory activity did not predict change in MDD status among persons with CTQ score below 33 ($\beta = 0.012$, $SE = 0.028$, $p = .989$, $d = 0.017$). Thus, the results were consonant with H6 (refer to Table 5).

Discussion

The present study offers an advance on inflammation-depression relations by examining if an elevated latent factor consisting of IL-6, CRP, and fibrinogen levels predicted future 9-year change in MDD status using LCS approaches and moderator analyses. Consistent with the cytokine theory of depression, increased inflammation activity predicted *within-person* 9-year change in MDD status, over and above T1 MDD status, its autoregressive self-feedback parameter, and between-person variance. Notably, findings were partially consistent with expanded cytokine theories of depression (e.g., social safety theory; Slavich, 2020a); increased T1 inflammatory activity predicted future 9-year change in MDD status considerably more strongly in younger (vs. older) adults ($d = 0.137$ vs. 0.119), females (vs. males) ($d = 0.149$ vs. 0.042), persons with more (vs. less) chronic health issues ($d = 0.133$ vs. 0.065), lower (vs. higher) income earners ($d = 0.161$ vs. 0.050), and those exposed to more (vs. less) childhood trauma frequency ($d = 0.156$ vs. 0.017). Overall, this pattern of results concurs with and extends a meta-analysis of 11 prospective studies which showed that excessive IL-6 and CRP serum levels predicted future heightened depression, with small yet substantial effect sizes in diverse populations ($d = 0.092$ – 0.138) (Valkanova et al., 2013). Further, our effect sizes for significant findings ($d = 0.123$ – 0.163) were about 1.5 to 2 times the effect size ($d = 0.07$) reported by Lamers et al. (2019) who tested the effect of increased IL-6 and CRP levels on MDD diagnosis in adults across 2 to 6 years. They were also higher than the small but significant effect ($d = 0.08$) observed in the meta-analysis of

cross-sectional studies by Howren, Lamkin, and Suls (2009). Potential accounts for these effects are discussed as follows.

Importantly, the results support expanded cytokine frameworks of depression (e.g., social signal transduction theory of depression; Slavich, 2020b) that thoroughly consider biopsychosocial vulnerabilities as moderators. The effect of increased inflammatory activity predicting 9-year change in MDD status was larger in women and younger adults. The gender difference is consistent with recent findings that increased CRP predicted subsequent depression severity more strongly in older adult women than men (Hiles et al., 2015; Niles, Smirnova, Lin, & O'Donovan, 2018). This pattern may be explained by ruminative tendencies in women as well as sex hormonal changes and menopause-related biological processes that can build up chronic systemic inflammation (Abu-Taha et al., 2009; Moieni et al., 2015; Slavich & Sacher, 2019; Zoccola, Figueroa, Rabideau, Woody, & Benencia, 2014). Alternatively, given higher prevalence and variability of depressive symptoms in women than men (Salk, Hyde, & Abramson, 2017), the null effect of inflammatory activity on MDD status change among men herein might be due to reduced variability in MDD severity and inflammation levels (as shown in Table S2).

Regarding age, the stronger effect in younger (vs. older) adults is counter-intuitive because older adults accrue higher levels of inflammation in the bloodstream and face greater risk of chronic illnesses (Chung et al., 2011). However, this finding appears to be due to the unusually healthy above 80 participants in the present study who showed relatively lower levels of number of chronic health conditions at T2 compared to most other age groups. Note that the age moderator analyses were no longer significant after removing these six older adults with outlying data from the analysis. In addition, the counter-intuitive age moderator result might be due to the fact that age was significantly negatively correlated with childhood trauma frequency ($r = -0.123$) (as reflected in Table S3). Furthermore there was reduced variability of inflammation levels among older (vs. younger) adults (as reflected in Table S4). Future empirical work can test these ideas and determine the degree to which this pattern of findings is replicated.

Apart from demographic moderators, why was the effect of inflammatory activity on future 9-year change in MDD larger in persons with heightened frequency of childhood trauma exposure and number of chronic health conditions as well as persons with below-median income? Perhaps increased inflammatory activity over time raised hippocampal and amygdala dopaminergic activity that was instrumental in triggering fear conditioning, fear reactivity, and traumatic recall, particularly for those with more (vs. less) childhood trauma. This notion is consistent with the social signal transduction theory of depression (Slavich, 2020b) and abundant data (Gill, Luckenbaugh, Charney, & Vythilingam, 2010; Yang & Jiang, 2020), and future studies could test such a hypothesis. Relatedly, based on theory, those with elevated chronic health conditions and increased inflammatory activity could be at risk for MDD due to illness-related constraints. Such constraints might reduce the capacity to engage in pleasure-enhancing valued activities or to execute skills that confer a sense of agency over life situations. On that note, evidence has shown that increased levels of IL-6, CRP, and fibrinogen could persistently induce a set of illness behaviors, such as deficits in motivation, suboptimal diet and nutrition, and poor sleep quality, similar to

MDD (Dantzer, O'Connor, Freund, Johnson, & Kelley, 2008). Multi-wave studies could empirically test the conjecture that increased inflammatory activity and chronic health problems predict future MDD via suboptimal lifestyle choices. Also, consistent with the social signal transduction theory of depression, persons with below-median income and elevated inflammation displayed higher odds of developing future MDD plausibly due to persistent environmental stressors (e.g., limited access to quality healthcare and social services, substandard housing conditions). This idea aligns with ample evidence that chronic poverty exposure was related to dysregulated metabolism and immune response as well as wear-and-tear of physiological stress modulatory systems and mood regulation and executive functioning-linked brain regions across long periods (cf. review by Kim, Evans, Chen, Miller, & Seeman, 2018). It is also consistent with recent evidence that lower family income predicted higher pre- post-social stressor task-induced increase in IL-6 (Quinn, Stanton, Slavich, & Joormann, 2020). Health disparity researchers can continue to replicate and empirically examine these ideas.

With respect to the non-moderated main effect finding, why did increased IL-6, CRP, and fibrinogen predict within-person 9-year change in MDD status? Plausibly, based on cytokine theory, buildup of threat appraisal-induced peripheral markers of inflammatory activity may have been transported to the brain (Ramirez, Fornaguera-Trías, & Sheridan, 2017), and affected myeloid (Wohleb, McKim, Sheridan, & Godbout, 2015) and basal ganglia (Miller, 2009) cells in ways that heightened MDD symptoms (e.g., anhedonia, psychomotor slowing, social withdrawal) in the longterm. For instance, these markers of inflammatory activity could stimulate transmission of activated immune cells (e.g., monocytes) to the brain parenchyma and vasculature and impacted brain function over time (Wohleb, Powell, Godbout, & Sheridan, 2013). Empirical data suggests that other mechanisms might include the upregulation of amygdala-related negativity bias or threat hypervigilance in the long run (Inagaki, Muscatell, Irwin, Cole, & Eisenberger, 2012). Simultaneously, these markers of inflammatory activity could have down-regulated basal ganglia, nucleus accumbens, ventral striatum, or other reward responses-linked brain activity (Eisenberger, Moieni, Inagaki, Muscatell, & Irwin, 2017; Eisenberger et al., 2010; Inagaki et al., 2015). It might also weaken functional connectivity among those regions across protracted time-scales (Felger et al., 2016). Because high threat and low reward have been shown to be risk factors for depression (Nielson et al., 2021; Paulus & Yu, 2012; Rackoff & Newman, 2020), increased inflammatory activity might lead to depression via these factors. Additionally, based on literature, these markers might have crossed through leaky areas of the blood-brain barrier (e.g., circumventricular organs, choroid plexus) and merged with saturable transport molecules on the blood-brain barrier (Quan & Banks, 2007). Also, markers of inflammatory activity could have attached to peripheral afferent nerve fibers (e.g., vagus nerve) that thereby stimulated upward catecholaminergic brain fibers, and/or were reconverted into primary cytokine signals (D'Mello, Le, & Swain, 2009). Upcoming neuroimaging and animal studies can continue to shed light on the strength of evidence for these propositions.

This study has a number of limitations. Relations between MDD and inflammation have been found to be bidirectional and intricate (Dowlati et al., 2010). However, given that markers of inflammatory activity were measured only at baseline, we could not investigate such bidirectionality. Further, inflammation is a complex process and only a few biomarkers

were analyzed among a possible wide array of biomarkers to which the cytokine theory of depression could apply. Furthermore, the immune measurement approaches within the MIDUS dataset we used are dated and it is possible that additional recent methods would also lead to similar longterm effects. Additionally, the naturalistic prospective dataset of the current study precludes strong causal inferences. Moreover, the pattern of results may be explained by unmeasured third variables (e.g., genetics) (Gustavson et al., 2019) that deserve attention. In addition, future studies should evaluate if the results would be replicated with the use of DSM-5 compared to the DSM-III-R-consistent measures used herein. Relatedly, the self-report measure of childhood trauma frequency in adulthood might be subject to retrospective recall biases. Also, future research should recruit culturally and socio-economically diverse samples to increase generalizability of study findings. Limitations notwithstanding, study strengths include the well-powered sample size, use of an advanced data analytic technique, and inclusion of moderation analyses to understand complex interactions.

If the pattern of findings is replicated, some clinical implications merit consideration. Reducing levels of IL-6, CRP, and fibrinogen may successfully prevent the development or recurrence of future MDD. This may be achieved through alterations in diet and nutrition (e.g., N-acetyl-d-cysteine, omega-3 supplementation) and lifestyle (e.g., mindfulness meditation, cognitive-behavioral strategies, yoga, exercise) (Dutcher, Boyle, Eisenberger, Cole, & Bower, 2021; Felger, 2019; Taylor et al., 2009; Tolkien, Bradburn, & Murgatroyd, 2019). Further, tailoring treatment based on inflammation profiles may be beneficial as elevated markers of inflammatory activity can impede optimal psychopharmacological treatment response (Carvalho et al., 2013). Furthermore, the anti-depressant properties of anti-inflammatory drugs may work best for people with heightened depression (Raison et al., 2013). Clinical science can profit from future research using randomized controlled trials or other appropriate study designs to clarify these topics as part of efforts to develop *personalized treatments*.

The data used in this publication were made available by the Data Archive on University of Wisconsin – Madison Institute on Aging, 1300 University Avenue, 2245 MSC, Madison, Wisconsin 53706–1532. Since 1995 the Midlife Development in the United States (MIDUS) study has been funded by the following: John D. and Catherine T. MacArthur Foundation Research Network; National Institute on Aging (P01-AG020166); National Institute on Aging (U19-AG051426). The original investigators and funding agency are not responsible for the analyses or interpretations presented here. The current manuscript has been submitted solely to this journal and is not published, in press, or submitted elsewhere. None of the hypotheses and results in the present manuscript have been presented at a conference or meeting, posted on a listserv, shared on a website, or any other platform. This study was conducted in compliance with the American Psychological Association (APA) and Declaration of Helsinki ethical standards in the treatment of human participants and approved by the institutional review board (IRB). Informed consent was obtained from participants as per IRB requirements at Harvard University, Georgetown University, University of California at Los Angeles, and University of Wisconsin at Madison. Since this study used a publicly available dataset, it was exempt from additional IRB approval.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Author Note

Nur Hani Zainal, Michelle G. Newman, Department of Psychology, The Pennsylvania State University, University Park. The data used in this publication were made available by the Data Archive on University of Wisconsin - Madison Institute on Aging, 1300 University Avenue, 2245 MSC, Madison, Wisconsin 53706-1532. Since 1995 the Midlife Development in the United States (MIDUS) study has been funded by the following: John D. and Catherine T. MacArthur Foundation Research Network; National Institute on Aging (P01-AG020166); National Institute on Aging (U19-AG051426).

The original investigators and funding agency are not responsible for the analyses or interpretations presented here. The current manuscript has been submitted solely to this journal and is not published, in press, or submitted elsewhere. None of the hypotheses and results in the present manuscript have been presented at a conference or meeting, posted on a listserv, shared on a website, or any other platform. This study was conducted in compliance with the American Psychological Association (APA) and Declaration of Helsinki ethical standards in the treatment of human participants and approved by the institutional review board (IRB). Informed consent was obtained from participants as per IRB requirements at Harvard University, Georgetown University, University of California at Los Angeles, and University of Wisconsin at Madison. Since this study used a publicly available dataset, it was exempt from additional IRB approval.

References

- Abu-Taha M, Rius C, Hermenegildo C, Noguera I, Cerda-Nicolas J-M, Issekutz AC, ... Sanz M-J (2009). Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losartan. *Journal of Immunology*, 183, 1393. doi:10.4049/jimmunol.0803157
- American Psychiatric Association. (1987). *Diagnostic and statistical manual of mental disorders* (3rd, rev. ed.). Washington, DC: American Psychiatric Association.
- Bentler PM (1990). Comparative fit indexes in structural models. *Psychological Bulletin*, 107, 238–246. doi:10.1037/0033-2909.107.2.238 [PubMed: 2320703]
- Bernstein DP, & Fink L. (1998). *Childhood Trauma Questionnaire: A retrospective self-report manual*. San Antonio, TX: The Psychological Corporation.
- Beurel E, Toups M, & Nemeroff CB (2020). The bidirectional relationship of depression and inflammation: Double trouble. *Neuron*, 107, 234–256. doi:10.1016/j.neuron.2020.06.002 [PubMed: 32553197]
- Beutel ME, Glaesmer H, Wiltink J, Marian H, & Brähler E. (2010). Life satisfaction, anxiety, depression and resilience across the life span of men. *Aging Male*, 13, 32–39. doi:10.3109/13685530903296698 [PubMed: 19842788]
- Bialek K, Czarny P, Strycharz J, & Sliwinski T. (2019). Major depressive disorders accompanying autoimmune diseases – Response to treatment. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 95, 109678. doi:10.1016/j.pnpbp.2019.109678
- Butnoriene J, Bunevicius A, Saudargiene A, Nemeroff CB, Norkus A, Cicieniene V, & Bunevicius R. (2015). Metabolic syndrome, major depression, generalized anxiety disorder, and ten-year all-cause and cardiovascular mortality in middle aged and elderly patients. *International Journal of Cardiology*, 190, 360–366. doi:10.1016/j.ijcard.2015.04.122 [PubMed: 25939128]
- Capuron L, & Miller AH (2011). Immune system to brain signaling: Neuropsychopharmacological implications. *Pharmacology & Therapeutics*, 130, 226–238. doi:10.1016/j.pharmthera.2011.01.014 [PubMed: 21334376]
- Carvalho LA, Torre JP, Papadopoulos AS, Poon L, Juruena MF, Markopoulou K, ... Pariante CM (2013). Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. *Journal of Affective Disorders*, 148, 136–140. doi:10.1016/j.jad.2012.10.036 [PubMed: 23200297]

- Chu AL, Stochl J, Lewis G, Zammit S, Jones PB, & Khandaker GM (2019). Longitudinal association between inflammatory markers and specific symptoms of depression in a prospective birth cohort. *Brain, Behavior, and Immunity*, 76, 74–81. doi:10.1016/j.bbi.2018.11.007
- Chung HY, Lee EK, Choi YJ, Kim JM, Kim DH, Zou Y, ... Yu BP(2011). Molecular inflammation as an underlying mechanism of the aging process and age-related diseases. *Journal of Dental Research*, 90, 830–840. doi:10.1177/0022034510387794 [PubMed: 21447699]
- Clauss A. (1957). Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. *Acta Haematologica*, 17, 237–246. doi:10.1159/000205234 [PubMed: 13434757]
- D’Mello C, Le T, & Swain MG (2009). Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. *Journal of Neuroscience*, 29, 2089–2102. doi:10.1523/jneurosci.3567-08.2009 [PubMed: 19228962]
- Dantzer R, O’Connor JC, Freund GG, Johnson RW, & Kelley KW (2008). From inflammation to sickness and depression: When the immune system subjugates the brain. *Nature reviews. Neuroscience*, 9, 46–56. doi:10.1038/nrn2297
- de la Torre-Luque A, Ayuso-Mateos JL, Sanchez-Carro Y, de la Fuente J, & Lopez-Garcia P. (2019). Inflammatory and metabolic disturbances are associated with more severe trajectories of late-life depression. *Psychoneuroendocrinology*, 110, 104443. doi:10.1016/j.psyneuen.2019.104443
- Derry HM, Padin AC, Kuo JL, Hughes S, & Kiecolt-Glaser JK (2015). Sex differences in depression: Does inflammation play a role? *Current Psychiatry Reports*, 17, 78. doi:10.1007/s11920-015-0618-5 [PubMed: 26272539]
- DiLuca M, & Olesen J. (2014). The cost of brain diseases: A burden or a challenge? *Neuron*, 82, 1205–1208. doi:10.1016/j.neuron.2014.05.044 [PubMed: 24945765]
- Dismuke CE, & Egede LE (2010). Association between major depression, depressive symptoms and personal income in US adults with diabetes. *General Hospital Psychiatry*, 32, 484–491. doi:10.1016/j.genhospsych.2010.06.004 [PubMed: 20851268]
- Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, & Lanctôt KL (2010). A meta-analysis of cytokines in major depression. *Biological Psychiatry*, 67, 446–457. doi:10.1016/j.biopsych.2009.09.033 [PubMed: 20015486]
- Duvis HE, de Jonge P, Penninx BW, Na BY, Cohen BE, & Whooley MA (2011). Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: Prospective findings from the heart and soul study. *American Journal of Psychiatry*, 168, 913–920. doi:10.1176/appi.ajp.2011.10081163
- Dunlap WP, Cortina JM, Vaslow JB, & Burke MJ (1996). Meta-analysis of experiments with matched groups or repeated measures designs. *Psychological Methods*, 1, 170–177. doi:10.1037/1082-989x.1.2.170
- Dunst CJ, Hamby DW, & Trivette CM (2004). Guidelines for calculating effect sizes for practice-based research syntheses. *Centerscope*, 3, 1–10.
- Dutcher JM, Boyle CC, Eisenberger NI, Cole SW, & Bower JE (2021). Neural responses to threat and reward and changes in inflammation following a mindfulness intervention. *Psychoneuroendocrinology*, 125, 105114. doi:10.1016/j.psyneuen.2020.105114
- Eisenberger NI, Moieni M, Inagaki TK, Muscatell KA, & Irwin MR (2017). In sickness and in health: The co-regulation of inflammation and social behavior. *Neuropsychopharmacology*, 42, 242–253. doi:10.1038/npp.2016.141 [PubMed: 27480575]
- Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, & Irwin MR (2010). Inflammation-induced anhedonia: Endotoxin reduces ventral striatum responses to reward. *Biological Psychiatry*, 68, 748–754. doi:10.1016/j.biopsych.2010.06.010 [PubMed: 20719303]
- Eswarappa M, Neylan TC, Whooley MA, Metzler TJ, & Cohen BE (2019). Inflammation as a predictor of disease course in posttraumatic stress disorder and depression: A prospective analysis from the Mind Your Heart Study. *Brain, Behavior, and Immunity*, 75, 220–227. doi:10.1016/j.bbi.2018.10.012
- Fancourt D, & Steptoe A. (2020). The longitudinal relationship between changes in wellbeing and inflammatory markers: Are associations independent of depression? *Brain, Behavior, and Immunity*, 83, 146–152. doi:10.1016/j.bbi.2019.10.004

- Felger JC, Li Z, Haroon E, Woolwine BJ, Jung MY, Hu X, & Miller AH (2016). Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. *Molecular Psychiatry*, 21, 1358–1365. doi:10.1038/mp.2015.168 [PubMed: 26552591]
- Felger JC (2019). Role of inflammation in depression and treatment implications. In Macaluso M. & Preskorn SH (Eds.), *Antidepressants: From Biogenic Amines to New Mechanisms of Action* (pp. 255–286). Cham: Springer International Publishing. doi: 10.1007/164_2018_166
- Friedman EM, & Herd P. (2010). Income, education, and inflammation: Differential associations in a national probability sample (The MIDUS Study). *Psychosomatic Medicine*, 72, 290–300. doi:10.1097/psy.0b013e3181cfe4c2 [PubMed: 20100883]
- Gill J, Luckenbaugh D, Charney D, & Vythilingam M. (2010). Sustained elevation of serum interleukin-6 and relative insensitivity to hydrocortisone differentiates posttraumatic stress disorder with and without depression. *Biological Psychiatry*, 68, 999–1006. doi:10.1016/j.biopsych.2010.07.033 [PubMed: 20951370]
- Gimeno D, Kivimäki M, Brunner EJ, Elovainio M, De Vogli R, Steptoe A, ... Ferrie JE(2009). Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. *Psychological Medicine*, 39, 413–423. doi:10.1017/S0033291708003723 [PubMed: 18533059]
- Graham JW (2005). Structural equation modeling. Unpublished Manuscript, The Pennsylvania State University.
- Grimm KJ, Ram N, & Hamagami F. (2011). Nonlinear growth curves in developmental research. *Child Development*, 82, 1357–1371. doi:10.1111/j.1467-8624.2011.01630.x [PubMed: 21824131]
- Grimm KJ, & Ram N. (2018). Latent growth and dynamic structural equation models. *Annual Review of Clinical Psychology*, 14, 55–89. doi:10.1146/annurev-clinpsy-050817-084840
- Gustavson DE, Franz CE, Panizzon MS, Reynolds CA, Xian H, Jacobson KC, ... Kremen WS (2019). Genetic and environmental associations among executive functions, trait anxiety, and depression symptoms in middle age. *Clinical Psychological Science*, 7, 127–142. doi:10.1177/2167702618805075 [PubMed: 30923645]
- Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, & Kivimäki M. (2015). Cumulative meta-analysis of interleukins 6 and 1 β , tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. *Brain, Behavior, and Immunity*, 49, 206–215. doi:10.1016/j.bbi.2015.06.001
- Hamer M, Molloy GJ, de Oliveira C, & Demakakos P. (2009). Leisure time physical activity, risk of depressive symptoms, and inflammatory mediators: The English Longitudinal Study of Ageing. *Psychoneuroendocrinology*, 34, 1050–1055. doi:10.1016/j.psyneuen.2009.02.004 [PubMed: 19272716]
- Haroon E, & Miller AH (2017). Inflammation effects on brain glutamate in depression: Mechanistic considerations and treatment implications. In Dantzer R. & Capuron L. (Eds.), *Inflammation-associated depression: Evidence, mechanisms and implications* (pp. 173–198). Cham: Springer International Publishing. doi: 10.1007/7854_2016_40
- Heinrich PC, Castell JV, & Andus T. (1990). Interleukin-6 and the acute phase response. *The Biochemical Journal*, 265, 621–636. doi:10.1042/bj2650621 [PubMed: 1689567]
- Herrick S, Blanc-Brude O, Gray A, & Laurent G. (1999). Fibrinogen. *International Journal of Biochemistry and Cell Biology*, 31, 741–746. doi:10.1016/S1357-2725(99)00032-1 [PubMed: 10467729]
- Hiles SA, Baker AL, de Malmanche T, & Attia J. (2012). Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. *Psychological Medicine*, 42, 2015–2026. doi:10.1017/S0033291712000128 [PubMed: 22336436]
- Hiles SA, Baker AL, de Malmanche T, McEvoy M, Boyle M, & Attia J. (2015). Unhealthy lifestyle may increase later depression via inflammation in older women but not men. *Journal of Psychiatric Research*, 63, 65–74. doi:10.1016/j.jpsychires.2015.02.010 [PubMed: 25795094]
- Höfler M. (2005). Causal inference based on counterfactuals. *BMC Medical Research Methodology*, 5, 28. doi:10.1186/1471-2288-5-28 [PubMed: 16159397]
- Hostinar CE, Lachman M, Mroczek D, Seeman T, & Miller G. (2015). Additive contributions of childhood adversity and recent stressors to inflammation at midlife: Findings from the

- MIDUS study. *Developmental Psychology*, 51 11, 1630–1644. doi:10.1037/dev0000049 [PubMed: 26389605]
- Hostinar CE, Davidson RJ, Graham EK, Mroczek DK, Lachman ME, Seeman TE, ... Miller GE (2017). Frontal brain asymmetry, childhood maltreatment, and low-grade inflammation at midlife. *Psychoneuroendocrinology*, 75, 152–163. doi:10.1016/j.psyneuen.2016.10.026 [PubMed: 27829190]
- Howren MB, Lamkin DM, & Suls J. (2009). Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. *Psychosomatic Medicine*, 71, 171–186. doi:10.1097/PSY.0b013e3181907c1b [PubMed: 19188531]
- Huang FL (2018). Multilevel modeling and ordinary least squares regression: How comparable are they? *Journal of Experimental Education*, 86, 265–281. doi:10.1080/00220973.2016.1277339
- Iacobucci D, Posavac SS, Kardes FR, Schneider MJ, & Popovich DL (2015). The median split: Robust, refined, and revived. *Journal of Consumer Psychology*, 25, 690–704. doi:10.1016/j.jcps.2015.06.014
- Inagaki TK, Muscatell KA, Irwin MR, Cole SW, & Eisenberger NI (2012). Inflammation selectively enhances amygdala activity to socially threatening images. *Neuroimage*, 59, 3222–3226. doi:10.1016/j.neuroimage.2011.10.090 [PubMed: 22079507]
- Inagaki TK, Muscatell KA, Irwin MR, Moieni M, Dutcher JM, Jevtic I, ... Eisenberger (2015). The role of the ventral striatum in inflammatory-induced approach toward support figures. *Brain, Behavior, and Immunity*, 44, 247–252. doi:10.1016/j.bbi.2014.10.006
- Jacobson NC, & Newman MG (2016). Perceptions of close and group relationships mediate the relationship between anxiety and depression over a decade later. *Depression and Anxiety*, 33, 66–74. doi:10.1002/da.22402 [PubMed: 26290461]
- Jacobson NC, & Newman MG (2014). Avoidance mediates the relationship between anxiety and depression over a decade later. *Journal of Anxiety Disorders*, 28, 437–445. doi:10.1016/j.janxdis.2014.03.007 [PubMed: 24858656]
- Kang H-J, Bae K-Y, Kim S-W, Kim J-T, Park M-S, Cho K-H, & Kim J-M (2016). Effects of interleukin-6, interleukin-18, and statin use, evaluated at acute stroke, on post-stroke depression during 1-year follow-up. *Psychoneuroendocrinology*, 72, 156–160. doi:10.1016/j.psyneuen.2016.07.001 [PubMed: 27428088]
- Kessler RC, Andrews G, Mroczek D, Ustun B, & Wittchen H-U (1998). The World Health Organization Composite International Diagnostic Interview short-form (CIDI-SF). *International Journal of Methods in Psychiatric Research*, 7, 171–185. doi:10.1002/mpr.47
- Kessler RC, & Üstün TB (2004). The World Mental Health (WMH) Survey Initiative version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). *International Journal of Methods in Psychiatric Research*, 13, 93–121. doi:10.1002/mpr.168 [PubMed: 15297906]
- Kessler RC, & Wang PS (2008). The descriptive epidemiology of commonly occurring mental disorders in the United States. *Annual Review of Public Health*, 29, 115–129. doi:10.1146/annurev.publhealth.29.020907.090847
- Kessler RC, Heeringa S, Lakoma MD, Petukhova M, Rupp AE, Schoenbaum M, ... Zaslavsky AM (2008). Individual and societal effects of mental disorders on earnings in the United States: results from the national comorbidity survey replication. *American Journal of Psychiatry*, 165, 703–711. doi:10.1176/appi.ajp.2008.08010126
- Khandaker GM, Pearson RM, Zammit S, Lewis G, & Jones PB (2014). Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: A population-based longitudinal study. *JAMA Psychiatry*, 71, 1121–1128. doi:10.1001/jamapsychiatry.2014.1332 [PubMed: 25133871]
- Kim P, Evans GW, Chen E, Miller G, & Seeman T. (2018). How socioeconomic disadvantages get under the skin and into the brain to influence health development across the lifespan. In Halfon N, Forrest CB, Lerner RM & Faustman EM (Eds.), *Handbook of life course health development* (pp. 463–497). Cham: Springer International Publishing. doi: 10.1007/978-3-319-47143-3_19
- Kim Y-K, Na K-S, Myint A-M, & Leonard BE (2016). The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression.

- Progress in Neuro-Psychopharmacology and Biological Psychiatry, 64, 277–284. doi:10.1016/j.pnpbp.2015.06.008 [PubMed: 26111720]
- Koenig W. (2003). Fibrin(ogen) in cardiovascular disease: an update. *Thrombosis and Haemostasis*, 89, 601–609. [PubMed: 12669113]
- Köhler-Forsberg O, Buttenschön HN, Tansey KE, Maier W, Hauser J, Dernovsek MZ, ... Mors O. (2017). Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. *Brain, Behavior, and Immunity*, 62, 344–350. doi:10.1016/j.bbi.2017.02.020
- Lamers F, Milaneschi Y, Smit JH, Schoevers RA, Wittenberg G, & Penninx BWJH (2019). Longitudinal association between depression and inflammatory markers: Results from the Netherlands study of depression and anxiety. *Biological Psychiatry*, 85, 829–837. doi:10.1016/j.biopsych.2018.12.020 [PubMed: 30819515]
- Lim S, & Jahng S. (2019). Determining the number of factors using parallel analysis and its recent variants. *Psychological Methods*, 24, 452–467. doi:10.1037/met0000230 [PubMed: 31180694]
- Love GD, Seeman TE, Weinstein M, & Ryff CD (2010). Bioindicators in the MIDUS national study: Protocol, measures, sample, and comparative context. *Journal of Aging and Health*, 22, 1059–1080. doi:10.1177/0898264310374355 [PubMed: 20876364]
- Lubbe D. (2019). Parallel analysis with categorical variables: Impact of category probability proportions on dimensionality assessment accuracy. *Psychological Methods*, 24, 339–351. doi:10.1037/met0000171 [PubMed: 29745684]
- Macleod CM, & Avery OT (1941). The occurrence during acute infections of a protein not normally present in the blood: II. Isolation and properties of the reactive protein. *Journal of Experimental Medicine*, 73, 183–190. doi:10.1084/jem.73.2.183
- Majd M, Saunders EFH, & Engeland CG (2020). Inflammation and the dimensions of depression: A review. *Frontiers in Neuroendocrinology*, 56, 100800. doi:10.1016/j.yfrne.2019.100800
- Maslowsky J, Jager J, & Hemken D. (2015). Estimating and interpreting latent variable interactions: A tutorial for applying the latent moderated structural equations method. *International Journal of Behavioral Development*, 39, 87–96. doi:10.1177/0165025414552301 [PubMed: 26478643]
- Matsunaga M. (2010). How to factor-analyze your data right: Do's, don'ts, and how-to's. *International Journal of Psychological Research*, 3, 97–110.
- McArdle JJ (2011). Longitudinal dynamic analyses of cognition in the health and retirement study panel. *Advances in Statistical Analysis*, 95, 453–480. doi:10.1007/s10182-011-0168-z [PubMed: 25598848]
- McArdle JJ (2009). Latent variable modeling of differences and changes with longitudinal data. *Annual Review of Psychology*, 60, 577–605. doi:10.1146/annurev.psych.60.110707.163612
- Miller AH, & Raison CL (2016). The role of inflammation in depression: From evolutionary imperative to modern treatment target. *Nature Reviews Immunology*, 16, 22–34. doi:10.1038/nri.2015.5
- Miller AH (2009). Mechanisms of cytokine-induced behavioral changes: Psychoneuroimmunology at the translational interface. *Brain, Behavior, and Immunity*, 23, 149–158. doi:10.1016/j.bbi.2008.08.006
- Miller AH, Haroon E, Raison CL, & Felger JC (2013). Cytokine targets in the brain: Impact on neurotransmitters and neurocircuits. *Depression and Anxiety*, 30, 297–306. doi:10.1002/da.22084 [PubMed: 23468190]
- Miller AH, Maletic V, & Raison CL (2009). Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. *Biological Psychiatry*, 65, 732–741. doi:10.1016/j.biopsych.2008.11.029 [PubMed: 19150053]
- Milrad SF, Hall DL, Jutagir DR, Lattie EG, Czaja SJ, Perdomo DM, ... Antoni MH (2018). Depression, evening salivary cortisol and inflammation in chronic fatigue syndrome: A psychoneuroendocrinological structural regression model. *International Journal of Psychophysiology*, 131, 124–130. doi:10.1016/j.ijpsycho.2017.09.009 [PubMed: 28918107]
- Moieni M, Irwin MR, Jevtic I, Olmstead R, Breen EC, & Eisenberger NI (2015). Sex differences in depressive and socioemotional responses to an inflammatory challenge: implications for sex

- differences in depression. *Neuropsychopharmacology*, 40, 1709–1716. doi:10.1038/npp.2015.17 [PubMed: 25598426]
- Morozink JA, Friedman EM, Coe CL, & Ryff CD (2010). Socioeconomic and psychosocial predictors of interleukin-6 in the MIDUS national sample. *Health Psychology*, 29, 626–635. doi:10.1037/a0021360 [PubMed: 20954777]
- Nielson DM, Keren H, O'Callaghan G, Jackson SM, Douka I, Vidal-Ribas P, ... Stringaris A. (2021). Great expectations: A critical review of and suggestions for the study of reward processing as a cause and predictor of depression. *Biological Psychiatry*, 89, 134–143. doi:10.1016/j.biopsych.2020.06.012 [PubMed: 32797941]
- Niles AN, Smirnova M, Lin J, & O'Donovan A. (2018). Gender differences in longitudinal relationships between depression and anxiety symptoms and inflammation in the health and retirement study. *Psychoneuroendocrinology*, 95, 149–157. doi:10.1016/j.psyneuen.2018.05.035 [PubMed: 29864671]
- Nusslock R, & Miller GE (2016). Early-life adversity and physical and emotional health across the lifespan: A neuroimmune network hypothesis. *Biological Psychiatry*, 80, 23–32. doi:10.1016/j.biopsych.2015.05.017 [PubMed: 26166230]
- Pariante CM, & Miller AH (2001). Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. *Biological Psychiatry*, 49, 391–404. doi:10.1016/S0006-3223(00)01088-X [PubMed: 11274650]
- Patten SB, Williams JVA, Lavorato DH, Wang JL, Jetté N, Sajobi TT, ... Bulloch AGM (2018). Patterns of association of chronic medical conditions and major depression. *Epidemiology and Psychiatric Sciences*, 27, 42–50. doi:10.1017/S204579601600072X [PubMed: 27784343]
- Paulus MP, & Yu AJ (2012). Emotion and decision-making: Affect-driven belief systems in anxiety and depression. *Trends in Cognitive Sciences*, 16, 476–483. doi:10.1016/j.tics.2012.07.009 [PubMed: 22898207]
- Páv M, Kovár H, Fiserová A, Havrdová E, & Lisá V. (2008). Neurobiological aspects of depressive disorder and antidepressant treatment: Role of glia. *Physiological Research*, 57, 151–164. [PubMed: 17465696]
- Quan N, & Banks WA (2007). Brain-immune communication pathways. *Brain, Behavior, and Immunity*, 21, 727–735. doi:10.1016/j.bbi.2007.05.005
- Quinn ME, Stanton CH, Slavich GM, & Joormann J. (2020). Executive control, cytokine reactivity to social stress, and depressive symptoms: Testing the social signal transduction theory of depression. *Stress*, 23, 60–68. doi:10.1080/10253890.2019.1641079 [PubMed: 31364435]
- Rackoff GN, & Newman MG (2020). Reduced positive affect on days with stress exposure predicts depression, anxiety disorders, and low trait positive affect 7 years later. *Journal of Abnormal Psychology*, 129, 799–809. doi:10.1037/abn0000639 [PubMed: 32914995]
- Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, ... Miller AH (2013). A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. *JAMA Psychiatry*, 70, 31–41. doi:10.1001/2013.jamapsychiatry.4 [PubMed: 22945416]
- Rajkowska G, & Miguel-Hidalgo JJ (2007). Gliogenesis and glial pathology in depression. *CNS & Neurological Disorders Drug Targets*, 6, 219–233. doi:10.2174/187152707780619326 [PubMed: 17511618]
- Ramirez K, Fornaguera-Trías J, & Sheridan JF (2017). Stress-induced microglia activation and monocyte trafficking to the brain underlie the development of anxiety and depression. *Current Topics in Behavioral Neurosciences*, 31, 155–172. doi:10.1007/7854_2016_25 [PubMed: 27352390]
- Revelle W. (2020). psych: Procedures for personality and psychological research, Northwestern University, Evanston, Illinois, USA, <https://CRAN.R-project.org/package=psych> Version = 2.0.9.
- Ridker PM (2016). From C-reactive protein to interleukin-6 to interleukin-1. *Circulation Research*, 118, 145–156. doi:10.1161/circresaha.115.306656 [PubMed: 26837745]
- Rose-John S. (2018). Interleukin-6 family cytokines. *Cold Spring Harbor Perspectives in Biology*, 10, a028415. doi:10.1101/cshperspect.a028415

- Rosellini AJ, & Brown TA (2021). Developing and validating clinical questionnaires. *Annual Review of Clinical Psychology*. doi:10.1146/annurev-clinpsy-081219-115343
- Rosseel Y. (2012). Lavaan: An R package for structural equation modeling. *Journal of Statistical Software*, 48, 1–36.
- Ryff CD, Almeida DM, Ayanian J, Binkley N, Carr DS, Coe C, ... Williams D. (2019a). Midlife in the United States (MIDUS 3), 2013–2014. Ann Arbor, MI: Interuniversity Consortium for Political and Social Research.
- Ryff CD, Seeman T, & Weinstein M. (2019b). Midlife in the United States (MIDUS 2): Biomarker Project, 2004–2009: Inter-university Consortium for Political and Social Research [distributor]
- Ryff CD, & Davidson RJ (2019). Midlife in the United States (MIDUS 2): Neuroscience Project, 2004–2009: Inter-university Consortium for Political and Social Research [distributor].
- Salk RH, Hyde JS, & Abramson LY (2017). Gender differences in depression in representative national samples: Meta-analyses of diagnoses and symptoms. *Psychological Bulletin*, 143, 783–822. doi:10.1037/bul0000102 [PubMed: 28447828]
- Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, Lewis DA, & Mirnics K. (2011). Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. *Molecular Psychiatry*, 16, 751–762. doi:10.1038/mp.2010.52 [PubMed: 20479761]
- Slavich GM, & Irwin MR (2014). From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. *Psychological Bulletin*, 140, 774–815. doi:10.1037/a0035302 [PubMed: 24417575]
- Slavich GM, & Sacher J. (2019). Stress, sex hormones, inflammation, and major depressive disorder: Extending social signal transduction theory of depression to account for sex differences in mood disorders. *Psychopharmacology*, 236, 3063–3079. doi:10.1007/s00213-019-05326-9 [PubMed: 31359117]
- Slavich GM (2020a). Social safety theory: A biologically based evolutionary perspective on life stress, health, and behavior. *Annual Review of Clinical Psychology*, 16, 265–295. doi:10.1146/annurev-clinpsy-032816-045159
- Slavich GM (2020b). Psychoneuroimmunology of stress and mental health. In Harkness KL & Hayden EP (Eds.), *The Oxford Handbook of Stress and Mental Health* (pp. 519–546). New York: Oxford University Press. doi: 10.1093/oxfordhb/9780190681777.013.24
- Smith KJ, Au B, Ollis L, & Schmitz N. (2018). The association between C-reactive protein, Interleukin-6 and depression among older adults in the community: A systematic review and meta-analysis. *Experimental Gerontology*, 102, 109–132. doi:10.1016/j.exger.2017.12.005 [PubMed: 29237576]
- Steiger JH (1980). Tests for comparing elements of a correlation matrix. *Psychological Bulletin*, 87, 245–251. doi:10.1037/0033-2909.87.2.245
- Taylor CB, Conrad A, Wilhelm FH, Strachowski D, Khaylis A, Neri E, ... Spiegel D. (2009). Does improving mood in depressed patients alter factors that may affect cardiovascular disease risk? *Journal of Psychiatric Research*, 43, 1246–1252. doi:10.1016/j.jpsychires.2009.05.006 [PubMed: 19577757]
- Tilleux S, & Hermans E. (2007). Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. *Journal of Neuroscience Research*, 85, 2059–2070. doi:10.1002/jnr.21325 [PubMed: 17497670]
- Ting EY-C, Yang AC, & Tsai S-J (2020). Role of interleukin-6 in depressive disorder. *International Journal of Molecular Sciences*, 21, 2194. doi:10.3390/ijms21062194
- Tolkien K, Bradburn S, & Murgatroyd C. (2019). An anti-inflammatory diet as a potential intervention for depressive disorders: A systematic review and meta-analysis. *Clinical Nutrition*, 38, 2045–2052. doi:10.1016/j.clnu.2018.11.007 [PubMed: 30502975]
- Tomarken AJ, & Waller NG (2005). Structural equation modeling: Strengths, limitations, and misconceptions. *Annual Review of Clinical Psychology*, 1, 31–65. doi:10.1146/annurev.clinpsy.1.102803.144239

- Treadway MT, Cooper JA, & Miller AH (2019). Can't or won't? Immunometabolic constraints on dopaminergic drive. *Trends in Cognitive Sciences*, 23, 435–448. doi:10.1016/j.tics.2019.03.003 [PubMed: 30948204]
- Valkanova V, Ebmeier KP, & Allan CL (2013). CRP, IL-6 and depression: A systematic review and meta-analysis of longitudinal studies. *Journal of Affective Disorders*, 150, 736–744. doi:10.1016/j.jad.2013.06.004 [PubMed: 23870425]
- Wang PS, Berglund P, & Kessler RC (2000). Recent care of common mental disorders in the United States: Prevalence and conformance with evidence-based recommendations. *Journal of General Internal Medicine*, 15, 284–292. doi:10.1046/j.1525-1497.2000.9908044.x [PubMed: 10840263]
- Watkins M. (2005). Determining parallel analysis criteria. *Journal of Modern Applied Statistical Methods*, 5, 344–346. doi:10.22237/jmasm/1162354020
- Wittchen H-U (1994). Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI): A critical review. *Journal of Psychiatric Research*, 28, 57–84. doi:10.1016/0022-3956(94)90036-1 [PubMed: 8064641]
- Wium-Andersen MK, Ørsted DD, Nielsen SF, & Nordestgaard BG (2013). Elevated C-reactive protein levels, psychological distress, and depression in 73 131 individuals. *JAMA Psychiatry*, 70, 176–184. doi:10.1001/2013.jamapsychiatry.102 [PubMed: 23266538]
- Wohleb ES, Powell ND, Godbout JP, & Sheridan JF (2013). Stress-induced recruitment of bone marrow-derived monocytes to the brain promotes anxiety-like behavior. *The Journal of Neuroscience*, 33, 13820–13833. doi:10.1523/jneurosci.1671-13.2013 [PubMed: 23966702]
- Wohleb ES, McKim DB, Sheridan JF, & Godbout JP (2015). Monocyte trafficking to the brain with stress and inflammation: A novel axis of immune-to-brain communication that influences mood and behavior. *Frontiers in Neuroscience*, 8, 447. doi:10.3389/fnins.2014.00447 [PubMed: 25653581]
- Yang J-J, & Jiang W. (2020). Immune biomarkers alterations in post-traumatic stress disorder: A systematic review and meta-analysis. *Journal of Affective Disorders*, 268, 39–46. doi:10.1016/j.jad.2020.02.044 [PubMed: 32158005]
- Zainal NH, & Newman MG (2021). Larger increase in trait negative affect is associated with greater future cognitive decline and vice versa across 23 years. *Depression and Anxiety*, 38, 146–160. doi:10.1002/da.23093 [PubMed: 32840954]
- Zainal NH, & Newman MG (in press-a). Depression and executive functioning bidirectionally impair one another across 9 years: Evidence from within-person latent change and cross-lagged models. *European Psychiatry*. doi:10.1192/j.eurpsy.2021.2217
- Zainal NH, & Newman MG (2019). Relation between cognitive and behavioral strategies and future change in common mental health problems across 18 years. *Journal of Abnormal Psychology*, 128, 295–304. doi:10.1037/abn0000428 [PubMed: 31045412]
- Zainal NH, & Newman MG (in press-b). Within-person increase in pathological worry predicts future depletion of unique executive functioning domains. *Psychological Medicine*. doi:10.1017/S0033291720000422
- Zalli A, Jovanova O, Hoogendijk WJG, Tiemeier H, & Carvalho LA (2016). Low-grade inflammation predicts persistence of depressive symptoms. *Psychopharmacology*, 233, 1669–1678. doi:10.1007/s00213-015-3919-9 [PubMed: 25877654]
- Zoccola PM, Figueroa WS, Rabideau EM, Woody A, & Benencia F. (2014). Differential effects of poststressor rumination and distraction on cortisol and C-reactive protein. *Health Psychology*, 33, 1606–1609. doi:10.1037/hea0000019 [PubMed: 24467256]

Table 1

Age Moderating T1 Inflammatory Activity Predicting T1-T2 Change in MDD Status

	<u>Younger</u>	<u>Older</u>
	β (SE)	β (SE)
Factor Loadings		
T1 Latent Inflammatory Activity		
T1 Log IL-6 Level	0.482	0.591
T1 Log CRP Level	0.833 *** (0.234)	0.813 *** (0.278)
T1 Log Fibrinogen Level	0.659 *** (0.037)	0.504 *** (0.040)
MDD Status	0.482	0.838
Regression Slopes		
T1 MDD Status \rightarrow T1-T2 MDD Status	-0.467 *** (0.101)	-0.833 *** (0.071)
T1 Inflammatory Activity \rightarrow T1-T2 MDD Status	0.085 * (0.041)	0.063 (0.035)
Model Fit Indices		
χ^2	43.396	
<i>df</i>	12	
<i>p</i>	< .001	
CFI	.940	
RMSEA	.075	

Note.

*
 $p < .05$;***
 $p < .001$.

β = unstandardized regression weight or standardized factor loading; = change across T1 and T2; CFI = confirmatory factor index; CRP = C-reactive protein; IL-6 = interleukin-6; *df* = degrees of freedom; MDD = major depressive disorder; RMSEA = root mean square error of approximation; SE = standard error; T1 = time 1; T2 = time 2.

Table 2

Gender Moderating T1 Inflammatory Activity Predicting T1-T2 Change in MDD Status

	Male	Female
	β (SE)	β (SE)
Factor Loadings		
T1 Latent Inflammatory Activity		
T1 Log IL-6 Level	0.585	0.644
T1 Log CRP Level	0.812 *** (0.298)	0.792 *** (0.193)
T1 Log Fibrinogen Level	0.598 *** (0.051)	0.567 *** (0.029)
MDD Status	0.900	0.523
Regression Slopes		
T1 MDD Status → T1-T2 MDD Status	-0.896 *** (0.062)	-0.513 *** (0.097)
T1 Inflammatory Activity → T1-T2 MDD Status	0.023 (0.037)	0.082 * (0.037)
Model Fit Indices		
χ^2	49.518	
<i>df</i>	12	
<i>p</i>	< .001	
CFI	.923	
RMSEA	.082	

Note.

*
p < .05;***
p < .001.

β = unstandardized regression weight or standardized factor loading; = change across T1 and T2; CFI = confirmatory factor index; CRP = C-reactive protein; IL-6 = interleukin-6; *df* = degrees of freedom; MDD = major depressive disorder; RMSEA = root mean square error of approximation; SE = standard error; T1 = time 1; T2 = time 2.

Table 3

Number of Chronic Health Conditions Moderating T1 Inflammatory Activity Predicting T1-T2 Change in MDD Status

	<u>0 to 2 Conditions</u>	<u>3 or More</u>
	β (SE)	β (SE)
Factor Loadings		
T1 Latent Inflammatory Activity		
T1 Log IL-6 Level	0.584	0.610
T1 Log CRP Level	0.867 *** (0.347)	0.790 *** (0.219)
T1 Log Fibrinogen Level	0.542 *** (0.043)	0.598 *** (0.038)
MDD Status	0.877	0.527
Regression Slopes		
T1 MDD Status \rightarrow T1-T2 MDD Status	-0.882 *** (0.068)	-0.567 *** (0.085)
T1 Inflammatory Activity \rightarrow T1-T2 MDD Status	0.043 (0.044)	0.074 * (0.036)
Model Fit Indices		
χ^2	54.363	
<i>df</i>	12	
<i>p</i>	< .001	
CFI	.908	
RMSEA	.087	

Note.

* $p < .05$;

*** $p < .001$.

β = unstandardized regression weight or standardized factor loading; = change across T1 and T2; CFI = confirmatory factor index; CRP = C-reactive protein; IL-6 = interleukin-6; *df* = degrees of freedom; MDD = major depressive disorder; RMSEA = root mean square error of approximation; SE = standard error; T1 = time 1; T2 = time 2.

Table 4

Income Moderating T1 Inflammatory Activity Predicting T1-T2 Change in MDD Status

	<u>Low Income</u>	<u>Median Income</u>
	β (SE)	β (SE)
Factor Loadings		
T1 Latent Inflammatory Activity		
T1 Log IL-6 Level	1.000	0.577
T1 Log CRP Level	0.638 *** (0.235)	0.820 *** (0.265)
T1 Log Fibrinogen Level	0.801 *** (0.036)	0.546 *** (0.043)
MDD Status	0.514	0.905
Regression Slopes		
T1 MDD Status \rightarrow T1-T2 MDD Status	-0.502 *** (0.098)	-0.901 *** (0.060)
T1 Inflammatory Activity \rightarrow T1-T2 MDD Status	0.096* (0.039)	0.025 (0.033)
Model Fit Indices		
χ^2	23.466	
<i>df</i>	12	
<i>p</i>	.024	
CFI	.976	
RMSEA	.045	

Note.

*
p < .05;***
p < .001.

β = unstandardized regression weight or standardized factor loading; = change across T1 and T2; CFI = confirmatory factor index; CRP = C-reactive protein; IL-6 = interleukin-6; *df* = degrees of freedom; MDD = major depressive disorder; RMSEA = root mean square error of approximation; SE = standard error; T1 = time 1; T2 = time 2.

Table 5

Childhood Trauma Frequency Moderating T1 Inflammatory Activity Predicting T1-T2 Change in MDD Status

	<u>Low Trauma</u>	<u>High Trauma</u>
	β (SE)	β (SE)
Factor Loadings		
T1 Latent Inflammatory Activity		
T1 Log IL-6 Level	0.589	0.625
T1 Log CRP Level	0.843 *** (0.300)	0.797 *** (0.217)
T1 Log Fibrinogen Level	0.508 *** (0.036)	0.645 *** (0.043)
MDD Status	1.902	1.620
Regression Slopes		
T1 MDD Status \rightarrow T1-T2 MDD Status	-1.921 *** (0.198)	-1.275 *** (0.146)
T1 Inflammatory Activity \rightarrow T1-T2 MDD Status	0.012 (0.047)	0.110 * (0.047)
Model Fit Indices		
χ^2	21.112	
<i>df</i>	11	
<i>p</i>	.032	
CFI	.979	
RMSEA	.045	

Note.

*
 $p < .05$;***
 $p < .001$.

β = unstandardized regression weight or standardized factor loading; = change across T1 and T2; CFI = confirmatory factor index; CRP = C-reactive protein; IL-6 = interleukin-6; *df* = degrees of freedom; MDD = major depressive disorder; RMSEA = root mean square error of approximation; SE = standard error; T1 = time 1; T2 = time 2.